Agilent Technologies Inc vs Ferrari NV — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Ferrari NV trades at $409.9 (market cap $71.67B). The key difference: Ferrari NV is the larger of the two by market cap, and Ferrari NV pays the higher dividend (1.04%). Which is the better fit depends on your goals.
| A | RACE | |
|---|---|---|
Market Cap | $42.00B | $71.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $504.09 |
52-Week Low | $110.24 | $314.63 |
Enterprise Value | $43.55B | $73.60B |
Dividend Yield | 0.69% | 1.04% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Ferrari (RACE) trades at $412.26, up 1.22% on the day, near its pivot point of $412. The stock exhibits strong bullish momentum in moving averages and has beaten earnings estimates for three consecutive quarters. Revenue and net income have grown steadily, with 2025 revenue reaching $7.15B and net income $1.60B, though valuation ratios like a P/E of 38.45 are elevated. Recent news highlights robust demand, particularly for vehicle personalization, and the company raised its 2026 guidance following a strong Q2.
The outlook remains positive given strong fundamentals, bullish analyst sentiment, and raised guidance, but risks include high valuation multiples, potential economic sensitivity, and execution challenges with new models like the Luce EV. The consensus price target of $462.67 suggests ~12% upside, supported by institutional confidence.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →